Results 291 to 300 of about 114,609 (356)
Chronic Diseases and Translational Medicine, EarlyView.Donanemab, approved by the U.S. FDA in July 2024, targets amyloid plaques in the brain to treat Alzheimer's disease in patients with mild cognitive impairment or mild dementia. ABSTRACT Substantial research has been conducted to identify an efficient treatment for Alzheimer's disease (AD).
Nandhini Jayaprakash +1 more
wiley +1 more source
Biosemiotic medicines: Symbolic formulations for placebo enhancements. [PDF]
J Educ Health PromotGoli F.
europepmc +1 more source
Psychotherapy and Placebos: Manifesto for Conceptual Clarity
Frontiers in Psychiatry, 2018 Charlotte R. Blease, Charlotte R. Blease
doaj +1 more source
Reducing Emotional Distress with Open-Label Placebos: Assessing the Role of Motor Engagement in Pill Consumption. [PDF]
Behav Sci (Basel)Schienle A, Kogler W.
europepmc +1 more source
Efficacy and safety evaluation of Allisartan Isoproxil in patients with hypertension: a meta-analysis. [PDF]
Front Cardiovasc MedZhao F, Liu Y, Chen L.
europepmc +1 more source
Double blind evaluation of dyphylline, theophylline and placebo for exercise induced bronchospasm
, 1982 C FURUKAWA +4 more
openalex +1 more source
Ultra-overt therapy: a novel medical approach centered on patient consciousness. [PDF]
Front Integr NeurosciShirbache K +6 more
europepmc +1 more source
GDF15 Analogues Acting as GFRAL Ligands
ChemMedChem, EarlyView.Considering the great importance of the GDF15/GRAL/RET signalling pathway, this review focuses on GDF15‐derived analogues able to act either as GFRAL agonists or antagonists, investigating their possible pharmacological applications in the treatment of GDF15‐related conditions, such as obesity and diabetes (agonist), or cancer‐induced nausea and ...
Andrea Di Santo +8 more
wiley +1 more source